It is shown that anti-tumor activity of melatonin in prostate cancer is mediated by IGF pathway in such a way that IGFBP3 is upregulated but IGF1R is downregulated after treatment of cancer cells by melatonin [142]. The gene discussed is IGF1; the disease is cancer.